0000899243-20-024183.txt : 20200903 0000899243-20-024183.hdr.sgml : 20200903 20200903183436 ACCESSION NUMBER: 0000899243-20-024183 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200901 FILED AS OF DATE: 20200903 DATE AS OF CHANGE: 20200903 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CATHERS BRIAN EDWIN CENTRAL INDEX KEY: 0001769127 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37539 FILM NUMBER: 201160272 MAIL ADDRESS: STREET 1: C/O GLOBAL BLOOD THERAPEUTICS, INC. STREET 2: 171 OYSTER POINT BLVD., SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc. CENTRAL INDEX KEY: 0001629137 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274825712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650741-7700 MAIL ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-09-01 0 0001629137 Global Blood Therapeutics, Inc. GBT 0001769127 CATHERS BRIAN EDWIN C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Scientific Officer Common Stock 2020-09-01 4 M 0 3750 A 8994 D Common Stock 2020-09-01 4 F 0 1551 60.45 D 7443 D Restricted Stock Units 2020-09-01 4 M 0 3750 0.00 D Common Stock 3750 18750 D Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 3,750 shares of Common Stock underlying the Reporting Person's RSUs. The shares of Common Stock underlying the RSUs vested with respect to 1/4th of the shares on March 1, 2020 and thereafter 1/6th of the remaining underlying shares shall vest in semi-annual installments over 3 years from March 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. /s/ Tricia Suvari, as Attorney-in-Fact 2020-09-03